Clinical trials of immunotherapy. Present status

D. L. Morton, James E Goodnight Jr

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This brief review of the more promising clinical trials suggests that immunotherapy is indeed beneficial for selected cancer patients. Because of its limited potency, it should not be used as primary treatment for malignant disease except as local immunotherapy for certain accessible tumours. It is effective for eradication of primary neoplasms of the skin as well as cutaneous metastases of malignant melanoma and breast carcinoma. The most important role for immunotherapy is in combination with other modalities. It may help control occult micrometastases that cause recurrence and death following surgical procedures or irradiation. Results of adjuvant immunotherapy appear promising for malignant melanoma, for carcinoma of the lung, breast, and colon, and for soft-tissue sarcomas. In combination with chemotherapy, immunotherapy appears to prolong remission and survival in acute myelogenous leukemia and in disseminated tumors of the lung and breast. Clearly, immunotherapy is not a panacea for malignant disease, but it could become an important arm in a multimodality attack on cancer.

Original languageEnglish (US)
Pages (from-to)2224-2233
Number of pages10
JournalCancer
Volume42
Issue number5
StatePublished - 1978

Fingerprint

Immunotherapy
Clinical Trials
Breast Neoplasms
Neoplasms
Lung
Neoplasm Micrometastasis
Skin Neoplasms
Combination Drug Therapy
Acute Myeloid Leukemia
Sarcoma
Cause of Death
Melanoma
Colon
Neoplasm Metastasis
Recurrence
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical trials of immunotherapy. Present status. / Morton, D. L.; Goodnight Jr, James E.

In: Cancer, Vol. 42, No. 5, 1978, p. 2224-2233.

Research output: Contribution to journalArticle

Morton, DL & Goodnight Jr, JE 1978, 'Clinical trials of immunotherapy. Present status', Cancer, vol. 42, no. 5, pp. 2224-2233.
Morton, D. L. ; Goodnight Jr, James E. / Clinical trials of immunotherapy. Present status. In: Cancer. 1978 ; Vol. 42, No. 5. pp. 2224-2233.
@article{83075c11b4ba40f6aea86817c7f24a60,
title = "Clinical trials of immunotherapy. Present status",
abstract = "This brief review of the more promising clinical trials suggests that immunotherapy is indeed beneficial for selected cancer patients. Because of its limited potency, it should not be used as primary treatment for malignant disease except as local immunotherapy for certain accessible tumours. It is effective for eradication of primary neoplasms of the skin as well as cutaneous metastases of malignant melanoma and breast carcinoma. The most important role for immunotherapy is in combination with other modalities. It may help control occult micrometastases that cause recurrence and death following surgical procedures or irradiation. Results of adjuvant immunotherapy appear promising for malignant melanoma, for carcinoma of the lung, breast, and colon, and for soft-tissue sarcomas. In combination with chemotherapy, immunotherapy appears to prolong remission and survival in acute myelogenous leukemia and in disseminated tumors of the lung and breast. Clearly, immunotherapy is not a panacea for malignant disease, but it could become an important arm in a multimodality attack on cancer.",
author = "Morton, {D. L.} and {Goodnight Jr}, {James E}",
year = "1978",
language = "English (US)",
volume = "42",
pages = "2224--2233",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical trials of immunotherapy. Present status

AU - Morton, D. L.

AU - Goodnight Jr, James E

PY - 1978

Y1 - 1978

N2 - This brief review of the more promising clinical trials suggests that immunotherapy is indeed beneficial for selected cancer patients. Because of its limited potency, it should not be used as primary treatment for malignant disease except as local immunotherapy for certain accessible tumours. It is effective for eradication of primary neoplasms of the skin as well as cutaneous metastases of malignant melanoma and breast carcinoma. The most important role for immunotherapy is in combination with other modalities. It may help control occult micrometastases that cause recurrence and death following surgical procedures or irradiation. Results of adjuvant immunotherapy appear promising for malignant melanoma, for carcinoma of the lung, breast, and colon, and for soft-tissue sarcomas. In combination with chemotherapy, immunotherapy appears to prolong remission and survival in acute myelogenous leukemia and in disseminated tumors of the lung and breast. Clearly, immunotherapy is not a panacea for malignant disease, but it could become an important arm in a multimodality attack on cancer.

AB - This brief review of the more promising clinical trials suggests that immunotherapy is indeed beneficial for selected cancer patients. Because of its limited potency, it should not be used as primary treatment for malignant disease except as local immunotherapy for certain accessible tumours. It is effective for eradication of primary neoplasms of the skin as well as cutaneous metastases of malignant melanoma and breast carcinoma. The most important role for immunotherapy is in combination with other modalities. It may help control occult micrometastases that cause recurrence and death following surgical procedures or irradiation. Results of adjuvant immunotherapy appear promising for malignant melanoma, for carcinoma of the lung, breast, and colon, and for soft-tissue sarcomas. In combination with chemotherapy, immunotherapy appears to prolong remission and survival in acute myelogenous leukemia and in disseminated tumors of the lung and breast. Clearly, immunotherapy is not a panacea for malignant disease, but it could become an important arm in a multimodality attack on cancer.

UR - http://www.scopus.com/inward/record.url?scp=0018246854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018246854&partnerID=8YFLogxK

M3 - Article

C2 - 363256

AN - SCOPUS:0018246854

VL - 42

SP - 2224

EP - 2233

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -